Form 4: Amgen Director Charles Holley Acquires Shares

Amgen Inc. Director Charles M. Holley acquired 128.9481 shares of common stock via dividend reinvestment.

Summary

• Director Charles M. Holley acquired 128.9481 shares of Amgen Inc. common stock on May 5, 2026.
• The acquisition was made at a price of $0 per share, representing dividend equivalents credited to unvested Restricted Stock Units.
• Following this transaction, the director holds 12,134.0331 shares directly and 1,260 shares indirectly through the Holley Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard dividend reinvestment activity by a director.

Positives

• Director maintains a significant equity stake in the company, signaling alignment with shareholder interests.

Negatives

• None.

Risks

• None.

Future Outlook

Not applicable as this is a routine disclosure of beneficial ownership changes.

Industry Context

StockSavvy.ai notes that routine dividend reinvestment by board members is a standard corporate governance practice that reflects long-term commitment to the issuer's equity.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation and equity incentive plan structures common among large-cap biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine acquisition of dividend equivalents.

Key Dates

Keywords

Amgen, AMGN, Insider Trading, Form 4, Dividend Reinvestment, Director Ownership